Evaluation of Inflammatory Markers in LARC Patients

Matosinhos Local Health Unit (ULSM)

Status: Completed

Conditions: Locally Advanced Rectal Cancer

Treatments: Diagnostic Test: Inflammatory markers

Study type: Observational

Funder types: Other

Identifiers

NCT05893667

HPedroHispano

Details and patient eligibility

About

Introduction: In locally advanced rectal cancers (LARC), TNM staging is far from optimal. We aimed to investigate the value of previously described circulating biomarkers as predictors of prognosis.

Methods: Retrospective analysis of 245 LARC patients diagnosed between January 2010 and December 2022, who underwent neoadjuvant chemoradiotherapy and surgery at two centers. A Cox regression and Kaplan-Meier analysis were performed.

Enrollment: 245 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients diagnosed pathologically with rectal adenocarcinomas, located within 12cm from the anal verge (measured by MRI), clinically staged T3-4 and/or N+ and treated with neoadjuvant chemoradiotherapy (nCRT) followed by radical surgery

Exclusion criteria

• evidence of distant metastasis at diagnosis, emergent or palliative surgery, local excision or "watch and wait" approach and evidence of inflammatory or hematological disorders

Trial design

245 participants in 2 patient groups

High levels of inflammatory scores

Treatment:

Diagnostic Test: Inflammatory markers

Low levels of inflammatory scores

Treatment:

Diagnostic Test: Inflammatory markers